Related Experiment Video
Updated: May 11, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Hepatitis B virus gene C1653T polymorphism mutation and hepatocellular carcinoma risk: an updated meta-analysis
Hua-Ping Shi1, Jun Zhang, Xue-Chai Shang
1Zhejiang University Medical College, 2Central Laboratory, Hang Zhou Red Cross Hospital, 3Laboratory Department, Sir Run Run Show Hospital of Zhejiang University Medical College, Hangzhou, China.
Abstract:
associations between the C1653T mutation and risk of HCC, the results have been inconsistent. We conducted searches of the published literature in Pubmed and Embase databases up to January 2013. Seventeen studies with a total of 1,085 HCC cases and 1,365 healthy controls were retrieved.We found a significant association between the C1653T mutation and HCC risk (OR = 2.01, 95%CI= 1.49-2.70). In the subgroup analysis by ethnicity, a significant association was also found in Asians (OR = 2.07, 95%CI= 1.71-2.51). In subgroup analysis by HBV genotype, B and C were linked with development of HCC (B:OR = 2.21, 95%CI= 1.13-4.34; C:OR = 2.26, 95%CI= 1.61-3.16). However, no significant association was found between the C1653T mutation and HCC risk in HBeAg positive cases. In conclusion, this meta-analysis suggests that the C1653T mutation may be associated with susceptibility to HCC.
Related Concept Videos
Hepatitis
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cancer Prevention
Some...
Pharmacogenomics: Identification of New Drug Targets
